Abbott Laboratories (XSWX:ABT) Beginning Cash Position: CHF6,709 Mil (As of Mar. 2026)


XSWX:ABT Abbott Laboratories XSWX:ABT
76 GF Score
Price CHF77.50
GF Value CHF105.27
View Full Analysis

What is Abbott Laboratories Beginning Cash Position?

Abbott Laboratories XSWX:ABT +1.97% 76 Beginning Cash Position is CHF6,709 Mil as of Mar. 2026. GuruFocus rates XSWX:ABT with a GF Score™ of 76/100 and a GF Value™ of CHF105.27.

Abbott Laboratories's Beginning Cash Position for the quarter that ended in Mar. 2026 was CHF6,709 Mil.

Abbott Laboratories's quarterly Beginning Cash Position increased from Sep. 2025 (CHF5,534 Mil) to Dec. 2025 (CHF5,986 Mil) and increased from Dec. 2025 (CHF5,986 Mil) to Mar. 2026 (CHF6,709 Mil).

Abbott Laboratories's annual Beginning Cash Position declined from Dec. 2023 (CHF8,546 Mil) to Dec. 2024 (CHF6,148 Mil) and declined from Dec. 2024 (CHF6,148 Mil) to Dec. 2025 (CHF6,069 Mil).

Abbott Laboratories Beginning Cash Position Related Terms

Abbott Laboratories Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories Beginning Cash Position Chart

Abbott Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,297.80 9,128.75 8,545.95 6,148.47 6,069.19

Abbott Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,729.50 5,311.82 5,533.69 5,985.52 6,709.37
XSWX:ABT
76GF Score
Abbott Laboratories XSWX:ABT
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbott Laboratories Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of CHF6,709 Mil mean?
Abbott Laboratories (XSWX:ABT) has a Beginning Cash Position of CHF6,709 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Abbott Laboratories and its competitors.
Is Abbott Laboratories' Beginning Cash Position too high?
Abbott Laboratories' current Beginning Cash Position is CHF6,709 Mil. Overall, Abbott Laboratories has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Beginning Cash Position compare to SYK and MDT?
Abbott Laboratories' Beginning Cash Position of CHF6,709 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Abbott Laboratories and its competitors. Abbott Laboratories's current Beginning Cash Position is CHF6,709 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Abbott Laboratories (XSWX:ABT) has a current Beginning Cash Position of CHF6,709 Mil. The stock's GF Value™ is CHF105.27, compared to a current price of CHF77.50 — trading 26.4% below its estimated fair value. The current Beginning Cash Position is CHF6,709 Mil. Abbott Laboratories' overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current Beginning Cash Position is CHF6,709 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued. The current stock price of CHF77.50 is trading 26.4% below its estimated GF Value™ of CHF105.27.

Key valuation signals for XSWX:ABT:

  • Beginning Cash Position: CHF6,709 Mil
  • GF Value™: CHF105.27 vs. price of CHF77.50 (26.4% below fair value)
  • GF Score™: 76/100

No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abbott Laboratories Business Description

Address 100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
76GF Score

Get the complete analysis for XSWX:ABT

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF77.50
Price
CHF105.27
GF Value